| P50 | author | Ann-Lii Cheng | Q38639483 |
| | Bang-Bin Chen | Q58313610 |
| | Chiun Hsu | Q88793010 |
| P2093 | author name string | C-H Hsu | |
| | Z-Z Lin | |
| | M-J Wang | |
| | D-L Ou | |
| | Y-Y Shao | |
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Q28296761 |
| | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 |
| | A review of the history, properties, and use of the immunomodulatory compound lenalidomide. | Q34173071 |
| | Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade | Q35065472 |
| | The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib | Q35584820 |
| | Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 |
| | Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma | Q37617052 |
| | Review article: the management of hepatocellular carcinoma | Q37635285 |
| | DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. | Q37660658 |
| | Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond | Q38619028 |
| | Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. | Q38629590 |
| | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 |
| | Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells | Q38801405 |
| | Computational genomics tools for dissecting tumour-immune cell interactions | Q38885361 |
| | Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma | Q38910274 |
| | Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients | Q39805787 |
| | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 |
| | T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. | Q40248504 |
| | Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 |
| | Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | Q42547622 |
| | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | Q43008115 |
| | Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design | Q43950860 |
| | Low-dose thalidomide treatment for advanced hepatocellular carcinoma | Q44681352 |
| | Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | Q45847529 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma | Q46642643 |
| | Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | Q47912802 |
| | Evolution: IMiDs to PPMs, revolution in DLBCL? | Q48149185 |
| | The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. | Q48707409 |
| | Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. | Q50522011 |
| | Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. | Q50856082 |
| | Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. | Q51372253 |
| | Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. | Q53073922 |
| | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. | Q53097045 |
| | Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma | Q58215154 |
| | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | Q58215181 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 722-730 | |
| P577 | publication date | 2017-08-17 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | |
| P478 | volume | 46 | |